

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Anthony Patrick JONES

Serial No.: To be assigned

Art Unit:

Filing Date: Concurrently herewith

Examiner:

For: *Medicament Dispenser*Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references listed on the attached form PTO-1449 as item nos. 10-13, 16-21 and 23-24 are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_. (37 CFR 1.98(d))
- ☒ A copy of the International Search Report which issued on International Application No. PCT/EP03/04402 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as item nos. 7 and 14-15, 22 and 25 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
  - (2) a notice of allowance under § 1.311,
- whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Robert J. Smith  
Attorney of Record  
Registration No. 40,820

Date: October 26, 2004  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-9616  
Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.</b> PG4808USw		<b>SERIAL NO.</b> To be assigned			
				<b>APPLICANT</b> Anthony Patrick JONES				10/512732	
				<b>FILING DATE</b> Concurrently herewith		<b>GROUP</b>			
<b>U.S. PATENT DOCUMENTS</b>									
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>		
	1.	4,518,861	05/21/1985	KREMPL et al.					
	2.	4,900,303	02/13/1990	LEMELSON					
	3.	5,020,527	06/04/1991	DESSERTINE					
	4.	5,452,711	09/26/1995	GAULT					
		5,468,961	11/21/1995	GRADON et al.					
	5.	5,544,647	08/13/1996	JEWETT et al.					
	6.	5,622,163	04/22/1997	JEWETT et al.					
	7.	5,794,612	08/18/1998	WACHTER et al.					
	8.	5,809,997	09/22/1998	WOLF					
	9.	6,029,659	02/29/2000	O'CONNOR					
Continue on page _____									
<b>FOREIGN PATENT DOCUMENTS</b>									
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>		
	10.	DE 3901963C		DE			X		
	11.	FR 2257351A	08/08/1975	FR			X		
	12.	WO 95/07723	03/23/1995	WIPO			X		
	13.	WO 95/07724	03/23/1995	WIPO			X		
	14.	EP 0689848	01/03/1996	EPO					
	15.	DE 19748725	05/06/1999	DE					
	16.	WO 99/65551	12/23/1999	WIPO			X		
	17.	WO 00/01612	01/13/2000	WIPO			X		
	18.	WO 00/16836	03/30/2000	WIPO			X		
	19.	GB 2342874	04/26/2000	GB			X		
	20.	WO 00/55072A	09/21/2000	WIPO			X		
	21.	DE 19934582A	01/25/2001	DE			X		
	22.	DE 19952314	05/17/2001	DE					
	23.	WO 01/41849	06/14/2001	WIPO			X		
	24.	WO 01/85241	11/15/2001	WIPO			X (Abstract)		
	25.	WO 02/36190	05/10/2002	WIPO					
Continue on page _____									
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>									
Continue on page _____									
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>				
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.									